Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics


Protagonist Therapeutics, Inc. (PTGX): $39.64

5.80 (+17.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PTGX POWR Grades


  • PTGX scores best on the Value dimension, with a Value rank ahead of 53.78% of US stocks.
  • PTGX's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • PTGX's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

PTGX Stock Summary

  • PTGX's price/sales ratio is 49.08; that's higher than the P/S ratio of 94.5% of US stocks.
  • With a year-over-year growth in debt of -66.49%, Protagonist Therapeutics Inc's debt growth rate surpasses just 5.05% of about US stocks.
  • As for revenue growth, note that PTGX's revenue has grown 1,244.69% over the past 12 months; that beats the revenue growth of 99.15% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Protagonist Therapeutics Inc are FIXX, FULC, MEIP, GRTS, and RKDA.
  • PTGX's SEC filings can be seen here. And to visit Protagonist Therapeutics Inc's official web site, go to www.protagonist-inc.com.

PTGX Stock Price Chart Interactive Chart >

Price chart for PTGX

PTGX Price/Volume Stats

Current price $39.64 52-week high $40.46
Prev. close $33.84 52-week low $14.16
Day low $33.58 Volume 864,300
Day high $40.46 Avg. volume 356,948
50-day MA $30.47 Dividend yield N/A
200-day MA $24.85 Market Cap 1.74B

Protagonist Therapeutics, Inc. (PTGX) Company Bio


Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.


PTGX Latest News Stream


Event/Time News Detail
Loading, please wait...

PTGX Latest Social Stream


Loading social stream, please wait...

View Full PTGX Social Stream

Latest PTGX News From Around the Web

Below are the latest news stories about Protagonist Therapeutics Inc that investors may wish to consider to help them evaluate PTGX as an investment opportunity.

Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera (PV), which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress. The conference call will take place on Friday, June 11, 2021, at 8:00 a.m. EDT (14:00 CEST).

Yahoo | June 7, 2021

Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera

Protagonist Therapeutics ("Protagonist" or "the Company") (Nasdaq: PTGX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV) for the reduction of erythrocytosis in those patients who do not require further treatment for thrombocytosis and/or leukocytosis. Breakthrough Therapy Designation requires that the drug candidate

Yahoo | June 3, 2021

Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor (IL-23R) antagonist peptide. This study is designed to determine the safety, tolerability, and pharmacokinetics of PN-232 in healthy volunteers. Recruitment for the study is ongoing.

Yahoo | May 24, 2021

2 ‘Strong Buy’ Momentum Stocks With Potential for Further Gains

Every rule has an exception, and a key to successful investing is knowing when to follow the rule – and when to follow the exception. So, while it’s true that past performance won’t ensure future gains, stocks that have shown strong and sustained gains, frequently show that past gains can build up a reliable momentum for further gains. The key is in the profile. Investors can look for stocks that offer a combination of two factors: strong, sustained gains and highly optimistic ratings from Wall Street’s analysts. Based on that profile, we’ve pulled up two stocks using TipRanks’ database.

Michael Marcus on TipRanks | May 21, 2021

2 Momentum Stocks With Potential for Further Gains

Every rule has an exception, and a key to successful investing is knowing when to follow the rule – and when to follow the exception. So, while it’s true that past performance won’t ensure future gains, stocks that have shown strong and sustained gains, frequently show that past gains can build up a reliable momentum for further gains. The key is in the profile. Investors can look for stocks that offer a combination of two factors: strong, sustained gains and highly optimistic ratings from Wall Street’s analysts. Based on that profile, we’ve pulled up two stocks using TipRanks’ database. Both have shown great momentum in the past year, and amassed enough bullish calls from analysts to be given “Strong Buy” consensus ratings. Let's take a closer look. Protagonist Therapeutics (PTGX) We’l...

Yahoo | May 21, 2021

Read More 'PTGX' Stories Here

PTGX Price Returns

1-mo 30.10%
3-mo 28.58%
6-mo 100.61%
1-year 144.99%
3-year 461.47%
5-year N/A
YTD 96.63%
2020 185.96%
2019 4.75%
2018 -67.64%
2017 -5.41%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7944 seconds.